1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Trinidad and Tobago Myasthenia Gravis Market Overview |
3.1 Trinidad and Tobago Country Macro Economic Indicators |
3.2 Trinidad and Tobago Myasthenia Gravis Market Revenues & Volume, 2021 & 2031F |
3.3 Trinidad and Tobago Myasthenia Gravis Market - Industry Life Cycle |
3.4 Trinidad and Tobago Myasthenia Gravis Market - Porter's Five Forces |
3.5 Trinidad and Tobago Myasthenia Gravis Market Revenues & Volume Share, By Treatment Type, 2021 & 2031F |
4 Trinidad and Tobago Myasthenia Gravis Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Growing elderly population (%) |
4.2.2 Neurological disorder prevalence (per 100k) |
4.2.3 Healthcare expenditure as % of GDP |
4.2.4 Number of neurologists per 100k population |
4.2.5 Availability of specialty care centers |
4.3 Market Restraints |
4.3.1 High cost of biologics (USD per dose) |
4.3.2 Limited insurance penetration (%) |
4.3.3 Low diagnosis rate (%) |
4.3.4 Limited clinical trials activity in region |
4.3.5 Dependence on imported drugs (%) |
4.4 Market Key Performance Indicators (KPIs) |
4.4.1 Annual diagnosed myasthenia gravis cases |
4.4.2 Treatment adherence rate (%) |
4.4.3 Time to diagnosis (average days) |
4.4.4 Relapse rate after treatment (%) |
4.4.5 Average treatment duration (months) |
5 Trinidad and Tobago Myasthenia Gravis Market Trends |
6 Trinidad and Tobago Myasthenia Gravis Market, By Types |
6.1 Trinidad and Tobago Myasthenia Gravis Market, By Treatment Type |
6.1.1 Overview and Analysis |
6.1.2 Trinidad and Tobago Myasthenia Gravis Market Revenues & Volume, By Treatment Type, 2021-2031F |
6.1.3 Trinidad and Tobago Myasthenia Gravis Market Revenues & Volume, By Drug Treatment, 2021-2031F |
6.1.4 Trinidad and Tobago Myasthenia Gravis Market Revenues & Volume, By Cholinestrase Inhibitors, 2021-2031F |
6.1.5 Trinidad and Tobago Myasthenia Gravis Market Revenues & Volume, By Chronic Immunomodulators, 2021-2031F |
6.1.6 Trinidad and Tobago Myasthenia Gravis Market Revenues & Volume, By Monoclonal Antibodies, 2021-2031F |
6.1.7 Trinidad and Tobago Myasthenia Gravis Market Revenues & Volume, By Rapid Immunotherapies, 2021-2031F |
6.1.8 Trinidad and Tobago Myasthenia Gravis Market Revenues & Volume, By Plasmapheresis, 2021-2031F |
6.1.9 Trinidad and Tobago Myasthenia Gravis Market Revenues & Volume, By Thymectomy, 2021-2031F |
6.1.10 Trinidad and Tobago Myasthenia Gravis Market Revenues & Volume, By Others, 2021-2031F |
7 Trinidad and Tobago Myasthenia Gravis Market Import-Export Trade Statistics |
7.1 Trinidad and Tobago Myasthenia Gravis Market Export to Major Countries |
7.2 Trinidad and Tobago Myasthenia Gravis Market Imports from Major Countries |
8 Trinidad and Tobago Myasthenia Gravis Market Key Performance Indicators |
9 Trinidad and Tobago Myasthenia Gravis Market - Opportunity Assessment |
9.1 Trinidad and Tobago Myasthenia Gravis Market Opportunity Assessment, By Treatment Type, 2021 & 2031F |
10 Trinidad and Tobago Myasthenia Gravis Market - Competitive Landscape |
10.1 Trinidad and Tobago Myasthenia Gravis Market Revenue Share, By Companies, 2024 |
10.2 Trinidad and Tobago Myasthenia Gravis Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |